<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05626842</url>
  </required_header>
  <id_info>
    <org_study_id>DR-EAM study Oviva</org_study_id>
    <secondary_id>IRAS ID: 269780</secondary_id>
    <nct_id>NCT05626842</nct_id>
  </id_info>
  <brief_title>The DR-EAM Type 2 Diabetes Study</brief_title>
  <official_title>The 'DR-EAM' Study - (Type 2) Diabetes Weight Reduction - Evaluation of Appcoaching Model</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oviva UK Ltd</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Westminster</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oviva UK Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this 12-month interventional study is to analyse the clinical outcome benefits,&#xD;
      scalability and cost-effectiveness of a digital Low-Calorie digital Type 2 diabetes mellitus&#xD;
      (T2DM) remission program compared to usual National Health System (NHS) care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Low-Calorie Diets (LCD) have recently gained popularity as a means of achieving an average&#xD;
      10kg weight loss, 10mmol/mol HbA1c reductions, 50% medication reductions, and Type 2 diabetes&#xD;
      mellitus (T2DM) remission (defined as blood-glucose levels &lt;48mmol/mol and off all&#xD;
      diabetes-related medications). If these clinical outcomes could be achieved at scale in the&#xD;
      United Kingdom, the potential savings for the National Health System (NHS) from reductions in&#xD;
      T2DM complications and medication costs are very significant. However, face-to-face T2DM LCD&#xD;
      programs are hard to scale due to challenges of accessibility, capacity, and cost.&#xD;
&#xD;
      This single-arm real-world evaluation with a matched control group from comparable GP&#xD;
      practices will evaluate clinical outcome benefits and NHS return on investment of a digital&#xD;
      LCD program with integrated behavior change intervention.&#xD;
&#xD;
      The 197 will be recruited from GP practices across South West London and Buckinghamshire.&#xD;
      Participants will complete a 12-week Total Diet Replacement (TDR) which involves a&#xD;
      low-calorie (800kcal/day), nutritionally complete diet, followed by a 4-week food-based&#xD;
      reintroduction period; and weight loss maintenance support monthly to 12 months. If a&#xD;
      participant gains more than 2kg in the maintenance phase, they have the option to follow a&#xD;
      TDR for an additional 4 weeks.&#xD;
&#xD;
      The intervention will be led by Diabetes Specialist Dietitians (DSD) via the Oviva app,&#xD;
      telephone, or video calls. All participants will have access to supporting learning&#xD;
      materials. Participants will receive intensive support in the first 16 weeks; follow-up&#xD;
      support for a further 36 weeks, plus a further 12 months of 'Active follow-up'. Participants&#xD;
      finish the trial at 24 months.&#xD;
&#xD;
      After completion, participants continue to receive free access to the Oviva app and their&#xD;
      connected monitoring devices.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 20, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary study objective-weight</measure>
    <time_frame>at baseline, 3, 6, 9,12 &amp; 24 months</time_frame>
    <description>Change in weight (kg) and BMI (kg/m2) continuously via BodyTrace scales</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary study objective- HbA1c</measure>
    <time_frame>at baseline, 6, 12 &amp; 24 months</time_frame>
    <description>Change in HbA1c- Diabetes remission defined as 2 HbA1c readings &lt; 48mmol/mol without diabetes medications at least 6 months apart</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary study objective- blood pressure</measure>
    <time_frame>at baseline, 12 &amp; 24 months</time_frame>
    <description>Change in blood pressure (systolic and diastolic) via British and Irish Hypertension Society validated monitors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary study objective- lipids</measure>
    <time_frame>at baseline, 12 &amp; 24 months</time_frame>
    <description>Change in lipid markers (total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides) via venous sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary study objective- physical activity</measure>
    <time_frame>at baseline, 3, 6, 9,12 &amp; 24 months</time_frame>
    <description>continuously via the Fitbit device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary study objective- quality of life</measure>
    <time_frame>at baseline, 6, 12 &amp; 24 months</time_frame>
    <description>change in quality of life via EQ-5D form</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary study objective- participant experience</measure>
    <time_frame>at 12 months</time_frame>
    <description>via NHS Friends &amp; Family Test standardised survey</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">197</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Single-arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-arm real-world evaluation with a matched control group from comparable GP practices</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Total Diet Replacement (800kcal/day)</intervention_name>
    <description>The TDR intervention involves a low-calorie, nutritionally complete diet for 12 weeks consuming four meal replacement products exclusively per day, followed by a 4-week food-based reintroduction period; and then weight loss maintenance support monthly for a further 36 weeks. If a patient gains more than 2kg in the maintenance phase, they have the option to follow a TDR for an additional 4 weeks.</description>
    <arm_group_label>Single-arm</arm_group_label>
    <other_name>TDR</other_name>
    <other_name>Low energy diet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Minimum age of 18 years&#xD;
&#xD;
          -  Maximum age of 65 years&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
          -  Minimum BMI of 27kg/m2 (adjusted to 25kg/m² in people of South Asian or Chinese&#xD;
             origin)&#xD;
&#xD;
          -  BMI &lt;45kg/m2&#xD;
&#xD;
          -  T2DM diagnosed at any time&#xD;
&#xD;
          -  HbA1c eligibility, most recent value, which must be within 12 months:&#xD;
&#xD;
          -  HbA1c ≥ 43 mmol/mol if on diabetes medication&#xD;
&#xD;
          -  HbA1c ≥ 48 mmol/mol if on diet alone&#xD;
&#xD;
          -  HBA1c &lt;108 mmol/mol&#xD;
&#xD;
          -  If HbA1c 90-108 mmol/mol, the value must be within 3 months of referral&#xD;
&#xD;
          -  On, or about to start, a second-line diabetes-related medication (metformin is&#xD;
             first-line)&#xD;
&#xD;
          -  Access to blood glucose monitoring equipment if on a sulphonylurea prior to referral&#xD;
&#xD;
          -  Ability to speak, read and receive care in English&#xD;
&#xD;
          -  Access to and willing to use an iOS or Android smart phone for the duration of the&#xD;
             intervention&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  T2DM either diet-controlled alone, or on metformin alone&#xD;
&#xD;
          -  Current insulin use&#xD;
&#xD;
          -  Pregnant or breastfeeding or considering pregnancy during next 6 months&#xD;
&#xD;
          -  Significant physical comorbidities:&#xD;
&#xD;
          -  Active cancer&#xD;
&#xD;
          -  Myocardial infarction or stroke within previous 6 months&#xD;
&#xD;
          -  Severe heart failure defined as equivalent to the New York Heart Association grade 3&#xD;
             (NYHA)&#xD;
&#xD;
          -  Recent eGFR &lt;30 mls/min/1.73 m2&#xD;
&#xD;
          -  Active live disease (except for NAFLD), or a history of hepatoma, or &lt;6 months of&#xD;
             onset of acute hepatitis&#xD;
&#xD;
          -  Severe angina, cardiac arrythmia including atrial fibrillation or prolonged QT&#xD;
             syndrome&#xD;
&#xD;
          -  Active substance use disorder / eating disorder&#xD;
&#xD;
          -  Porphyria&#xD;
&#xD;
          -  Weight loss &gt;5% body weight within last 6 months or on current weight management&#xD;
             programme or had/awaiting bariatric surgery (unless willing to come off waiting list)&#xD;
&#xD;
          -  Health professional assessment that the person is unable to understand or meet the&#xD;
             demands of the treatment programme and/or monitoring requirements, which may include&#xD;
             -Learning disabilities&#xD;
&#xD;
          -  Taking monoamine-oxidase inhibitor medication&#xD;
&#xD;
          -  Taking warfarin&#xD;
&#xD;
          -  Taking varenicline (smoking cessation medication)&#xD;
&#xD;
          -  Retinopathy diagnosis or lack of retinal screening in the last year&#xD;
&#xD;
          -  Active/investigation for gastric or duodenal ulcers&#xD;
&#xD;
          -  People currently participating in another clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lucy Jones</last_name>
    <role>Study Director</role>
  </overall_official>
  <location>
    <facility>
      <name>Oviva UK ltd</name>
      <address>
        <city>London</city>
        <zip>SE1 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 2, 2022</study_first_submitted>
  <study_first_submitted_qc>November 15, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2022</study_first_posted>
  <last_update_submitted>November 15, 2022</last_update_submitted>
  <last_update_submitted_qc>November 15, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 Diabetes</keyword>
  <keyword>Low calorie diet</keyword>
  <keyword>Total diet replacement</keyword>
  <keyword>behaviour change</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

